Novartis Gains Phase II COPD Agent In Deal Worth Up To $375 Mil.
This article was originally published in The Pink Sheet Daily
Novartis will assume Phase III testing of anti-muscarinic from U.K. companies Vectura and Arakis. AD 237 will be evaluated in head-to-head comparison against Pfizer/Boehringer Ingelheim's Spiriva; companies believe AD 237 has a better safety profile than tiotropium.
You may also be interested in...
PharmaKodex will apply novel oral and dermal delivery mechanisms to existing therapies.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.